ForSight Robotics raises $125M for cataract surgery tech

ForSight Robotics has secured $125 million in a Series B funding round led by Eclipse, with participation from strategic investors including board member Fred Moll, the Adani Group, Reiya Ventures, and existing backers. This latest round brings the company’s total funding to $195 million. The capital will accelerate the development and commercialization of ForSight’s Oryom platform, which is promoted as the world’s first robotic surgery system specifically designed for cataract and other eye disease treatments. Oryom integrates AI algorithms, advanced computer vision, and miniaturized mechanical components to enable precise, consistent, and ergonomically improved ophthalmic surgeries, with capabilities to access both anterior and posterior segments of the eye. ForSight plans to initiate first-in-human clinical trials of the Oryom system within the year. Co-founder and CMO Dr. Joseph Nathan emphasized ophthalmology as a significant new frontier for surgical robotics, comparable in market potential and clinical need to general surgery’s earlier robotics revolution. The platform aims to